| ￥3000 | |
| Z05420-100 | |
|
|
|
|
|
|
|
|
|
| Species | Human | ||||
| Protein Construction |
|
||||
| Purity |
> 95% as determined by BisTris PAGE > 95% as determined by HPLC |
||||
| Endotoxin Level | Less than 1EU per μg by the LAL method. | ||||
| Expression System | HEK293 | ||||
| Theoretical Molecular Weight | 65.66 kDa | ||||
| Apparent Molecular Weight | Due to glycosylation, the protein migrates to 75-95 kDa based on Bis-Tris PAGE result. | ||||
| Formulation | Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). | ||||
| Reconstitution | Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. | ||||
| Storage & Stability | Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
The purity of IL-1 R9 hFc Chimera, Human is greater than 95% as determined by SEC-HPLC. »
IL-1 R9 hFc Chimera, Human on Bis-Tris PAGE under reduced condition. The purity is greater than 95%. »
| Target Background | The interleukin 1 receptor (IL-1R) and the Toll-like receptors (TLRs) are highly homologous innate immune receptors that provide the first line of defense against infection. IL-1R have appeared for functions that do not require IL-1 ligand binding is supported by the case of the orphan receptors IL-1R10 and IL-1R9, which do not have known ligands and that have non-immune functions in the brain. |
| Synonyms | IL-1-RAPL-2; IL-1RAPL-2; IL1RAPL-2; IL-1R-9; IL-1R9; TIGIRR-1; IL1RAPL2; IL1R9 |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
